University of Notre Dame Endowment

Torigen Pharmaceuticals is dedicated to advancing immuno-oncology solutions for companion animals facing cancer. The company develops innovative immunotherapy treatments, notably an experimental autologous cancer vaccine that activates the immune system to target specific tumor-associated antigens. This approach allows for the detection and treatment of cancer without relying on invasive surgeries or chemotherapy, thereby improving the quality of care for animals. By leveraging years of scientific research, Torigen Pharmaceuticals aims to provide effective and less painful options for veterinary oncology, positioning itself at the forefront of cancer treatment for pets.

AgenDx is an early stage molecular diagnostics company developing a revolutionary cost-effective molecular diagnostics platform. Their novel technology allows simple molecular diagnostic lab-quality testing. With a quick sample-to-answer in minutes, their platform is positioned to transform where and how disease is detected and treated. Their platform accommodates a wide range of nucleic-acid based tests for infectious disease, cancer, and other chronic conditions including cardiovascular disease and arthritis. Their initial focus is to prove the AgenDx technology by developing tests for aiding physician’s treatment decisions for pancreatic cancer. Their platform is designed for operation by untrained users in clinical settings near the patient. The sample is collected and inserted into a disposable cartridge. A control system automates and runs the test. Clear results will be displayed and transmitted. Their proprietary system will accommodate any biological sample, including blood, saliva, and tissue.